Abstract
Introduction This study aimed to assess the effects of cancer treatment on sarcoma types and to predict overall survival probabilities using nomograms.
Methods This study uses the SEER-18 database, Version 2020, sponsored by the National Cancer Institute (NCI). The study cohort included participants diagnosed between 2000 and 2018 with soft tissue cancers including heart. A multivariable Cox proportional hazards model was applied to predict mortality rate, and nomograms were used to predict overall survival probability.
Results The median survival time for 24,849 study participants was 48 months (IQR: 19-102) with Spindle Cell Sarcoma (ScS) having a shorter median survival time compared with Liposarcoma (LiS). A significant number of STS patients had surgery, where surgery on ScS improved survival by 75% (HR: 0.25, 95%CI: 0.19-0.32, p<0.001) and those who received radiation had a 26% improvement (HR: 0.74, 95%CI: 0.61-0.89, p=0.001). Furthermore, chemotherapy on GcS resulted in a 40% reduction in mortality for patients compared to those who did not receive chemotherapy (HR 0.60, 95%CI:0.45-0.80, p<0.001). Based on nomogram, after two, five, and ten years, a patient who received surgery on their primary sites would have a survival rate of approximately 90 percent. In contrast, a patient who did not receive surgery on their primary sites would only live for 20 percent or less. Patients with MyS have a 90% chance of surviving for 5 and 10 years after surgery, but only 22% and 10% without surgery.
Conclusions Based on the results of this study, surgical and radiation intervention on sarcomas was associated with improved survival in patients with STS, while chemotherapy and primary systemic therapy had contradictory effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SEER Program is a population-based cancer database that geographically encompasses more than a quarter of the US population within its catchment areas (Hankey BF, et al., 1999). SEER program registries collect data on patient demographics, cancer type, stages, first course of treatment, and vital status (Hankey BF, et al., 1999; Frey CM, et al., 1992 ; Hankey BF, et al., 1999; Gamboa AC, et al., 2021). The study examined SEER Research Plus from 2000 through 2018 dataset 18 Registries case listings and collected data from 147 sub-setting cases
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all meta data will be provided upon request